viewAlgernon Pharmaceuticals Inc.

Algernon Pharmaceuticals says last patient treated in Phase 2b portion of Ifenprodil trial

Ifenprodil is being investigated as a potential treatment for COVID-19

Virus graphic
Algernon believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can cause the dangerous “cytokine storm” in COVID-19 patients

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) announced Thursday that it had treated the last patient in the Phase 2b portion of its multinational Phase 2b/3 study of Ifenprodil (NP-120), a potential COVID-19 treatment.

In a statement, the company said the patient had completed treatment as well as the required two-week follow up.

Vancouver-based Algernon recently announced positive trending interim data from the Phase 2b portion of the study. Full results are expected before the end of February.

READ: Algernon provides additional facts on its interim data for its Phase 2b/3 Ifenprodil COVID-19 study

CEO Christopher Moreau called the news “another important step” for the company.

“Now that we have announced final patient out of the Ifenprodil COVID-19 study, we can begin preparations for the final data report,” Moreau told shareholders.

Ifenprodil is an N-methyl-D-aspartate receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB) and prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.

Algernon believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can cause the dangerous “cytokine storm” that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients.

The firm cautioned it is not making any express or implied claim that Ifenprodil is effective against COVID-19 at this time.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.27 CAD

Market: CSE
Market Cap: $37.85 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...


Algernon Pharmaceuticals looks to highly regarded UK company to conduct...

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive with news the company has chosen renowned contract research organization Hammersmith Medicines Research located in the UK to conduct their Phase 1 stroke program study using...

3 days, 21 hours ago

2 min read